Bahjat Laboratory

My research group is interested in understanding the signals that regulate the expansion and function of CD8+ T cells, and why seemingly healthy, normal T cells would be rendered incapable of killing their intended target. The laboratory utilizes models of microbial infection to elicit a robust, well-characterized T cell response.

Genitourinary Cancer Research

Brendan D. Curti, M.D., focuses on developing immunotherapies to treat malignancies of the prostate, kidney and bladder.

Integrated Therapies Laboratory

The Integrated Therapies Laboratory is a collaborative research effort between Michael J. Gough, Ph.D., and Marka R. Crittenden, M.D., Ph.D. It encompasses their overlapping research interest into the ability of cytotoxic therapy to provide large-scale cancer cell death in vivo, while modifying the profile of immune cells within the tumor.

Laboratory of Basic Immunology

The main focus of the Laboratory of Basic Immunology, led by Andrew D. Weinberg, Ph.D., is to understand T cell activation during disease states.

Laboratory of Cancer Immunobiology

The long-term goal of the Laboratory of Cancer Immunobiology, led by Hong-Ming Hu, Ph.D., is to understand how the immune system senses tumor cells and develop effective cancer vaccines and immunotherapy strategies.

Laboratory of Immunologic Monitoring

The Laboratory of Immunologic Monitoring measures patients' immune responses to different anti-cancer immunotherapy interventions, such as experimental cancer vaccines, to assess their effectiveness.

Laboratory of Molecular and Tumor Immunology

The Laboratory of Molecular and Tumor Immunology, led by Bernard A. Fox, Ph.D., hypothesizes that a primary reason for the failure of past tumor vaccine strategies is that the magnitude of the antitumor immune response is insufficient to mediate tumor regression. One answer to this is to create a lymphopenic host, reconstitute that host with lymphocytes and then inoculate with a tumor vaccine.

Lung Cancer Research

Providence Thoracic Oncology Program emphasizes a multidisciplinary approach to cancer management.  Our clinical trials program offers a broad array of innovative clinical research, including studies of new surgical techniques, radiation, chemotherapy, targeted therapy and immunotherapy agents, and tissue banking.  Rachel E. Sanborn, M.D., specializes in thoracic oncology and clinical research, studying new agents or combinations in the treatment of lung cancer, mesothelioma and other thoracic tumors.

Redmond Laboratory

The goal of the laboratory, led by William L. Redmond, Ph.D., is to determine the molecular mechanisms by which tumors induce immune suppression. Ultimately, understanding how tumors escape destruction by the immune system will guide the development of novel anti-tumor therapies.